imidapril (tanatril) Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Imidapril, sold under the brand name Tanatril among others, is an ACE inhibitor used as an antihypertensive drug and for the treatment of chronic heart failure.   Wikipedia

Chemistry

  • SMILES: CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2[C@@H](CN(C)C2=O)C(=O)O
  • InChIKey: KLZWOWYOHUKJIG-BPUTZDHNSA-N
  • Mol. Mass: 405.45
  • ALogP: 0.88
  • ChEMBL Molecules:
    imidapril  
    imidaprilat  
More Chemistry

Pharmacology

Alternative names

1-methyl-3-(2-(n-(1-ethoxycarbonyl-3-phenylpropyl)amino)propionyl)-2-oxoimidazolidine-4-carboxylic acid | 4-imidazolidinecarboxylic acid, 3-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1-methyl-2-oxo-, monohydrochloride, (4s-(3(r*(r*)),4r*))- | imidapril | imidaprilat | imidapril hcl | imidapril hydrochloride | ta 6366 | ta-6366 | tanatril

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Albuminuria (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Essential Hypertension (Phase 3)

Heart Failure ()

Hypertension (Phase 3)

Polycystic Kidney, Autosomal Dominant (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue